The Fengyuan pharmaceutical industry has invested more than $ four in projects

From the study of new drugs to the expansion of the scope of commercial circulation of medicine, Fengyuan Medicine announced four investment bills today, totaling about $130 million to complete.　　These 4 motions include: The bill on joint venture with Anhui Human Science and Technology Co., Ltd., a motion on cooperation in the development of new drugs with Beijing Polytechnic University, a motion on the Suzhou Investment Project and a proposal for the technical improvement project of the plastic bottle water needle production line of the wholly-owned subsidiary. Among them, the company and the human technology in July 12 has signed a "joint venture contract", the two sides agreed to invest in Anhui province Hefei investment in the establishment of "Anhui Fengyuan Pharmaceutical Industry Co., Ltd.". The registered capital of the JV Company is RMB 83.33 million.　　Among them, Fengyuan Pharmaceutical Holdings 60%. The joint venture company's drug development and production mainly by the Chinese people's technology to bear.　　The contract stipulates that human science and technology to ensure the effectiveness and legality of the clinical approvals of cisplatin and methotrexate implants for anticancer drugs, until the JV company obtains the new drug certificate and the production approval, if the problem of drug Administration leads to the inability to obtain the production documents, all the previous clinical trial costs are borne by the Chinese technology In the study of new drugs, the company will also commissioned Beijing Institute of Technology and Beijing Institute of Science and Technology Development Center Co., Ltd. to develop the treatment of hepatitis B virus and cancer adjuvant treatment of new drugs. Among them, the treatment of hepatitis B New drug research and development of the investment budget of 13 million yuan, for cancer adjuvant treatment of new drug research and development of the investment budget of 20 million yuan.　　The company said that the new drug research and development results and related knowledge property rights are shared by both sides, Fengyuan pharmaceutical industry has exclusive right to use. In addition, the Fengyuan pharmaceutical industry will expand the scope of the pharmaceutical business. The company intends to invest 30 million yuan in the Suzhou economic development Zone to invest in new medical logistics warehousing projects. In addition, the company also intends to invest 21 million yuan in Bengbu Fengyuan Paint Mountain Pharmaceutical Co., Ltd. glass bottle water needle production line to transform.